These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
26. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. McMullen M; Karakasis K; Madariaga A; Oza AM Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32560564 [TBL] [Abstract][Full Text] [Related]
27. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related]
29. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of PARP inhibitors in breast cancer. Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747 [TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674 [TBL] [Abstract][Full Text] [Related]
32. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995 [TBL] [Abstract][Full Text] [Related]
34. Recent advances in cancer therapy using PARP inhibitors. Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646 [TBL] [Abstract][Full Text] [Related]
35. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Helleday T Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of PARP inhibitor resistance in ovarian cancer. Kubalanza K; Konecny GE Curr Opin Obstet Gynecol; 2020 Feb; 32(1):36-41. PubMed ID: 31815769 [TBL] [Abstract][Full Text] [Related]
37. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. De Lorenzo SB; Patel AG; Hurley RM; Kaufmann SH Front Oncol; 2013 Sep; 3():228. PubMed ID: 24062981 [TBL] [Abstract][Full Text] [Related]